The TM6SF2 E167K and PNPLA3 I148M polymorphisms may have additive effects on lipid metabolism and the development of NAFLD by upregulating the expression of SREBP-1c and FASN. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.